Atorvastatin increases exercise leg blood flow in healthy adults.
OBJECTIVE
We sought to examine the effect of atorvastatin therapy on exercise leg blood flow in healthy middle-aged and older-men and women.


BACKGROUND
The vasodilatory response to exercise decreases in humans with aging and disease and this reduction may contribute to reduced exercise capacity.


METHODS
We used a double-blind, randomly assigned, placebo-controlled protocol to assess the effect of atorvastatin treatment on exercising leg hemodynamics. We measured femoral artery blood flow (FBF) using Doppler ultrasound and calculated femoral vascular conductance (FVC) from brachial mean arterial pressure (MAP) before and during single knee-extensor exercise in healthy adults (ages 40-71) before (PRE) and after (POST) 6 months of 80 mg atorvastatin (A: 14 men, 16 women) or placebo (P: 14 men, 22 women) treatment. FBF and FVC were normalized to exercise power output and estimated quadriceps muscle mass.


RESULTS
Atorvastatin reduced LDL cholesterol by approximately 50%, but not in the placebo group (p < 0.01). Atorvastatin also increased exercise FBF from 44.2 ± 19.0 to 51.4 ± 22.0 mL/min/W/kg muscle whereas FBF in the placebo group was unchanged (40.1 ± 16.0 vs. 39.5 ± 16.1) (p < 0.01). FVC also increased with atorvastatin from 0.5 ± 0.2 to 0.6 ± 0.2 mL/min/mmHg/W/kg muscle, but not in the placebo subjects (P: 0.4 ± 0.2 vs. 0.4 ± 0.2) (p < 0.01).


CONCLUSIONS
High-dose atorvastatin augments exercising leg hyperemia. Statins may mitigate reductions in the exercise vasodilatory response in humans that are associated with aging and disease.
Henry Low Heart Center, Department of Cardiology, Hartford Hospital, Hartford, CT 06102, USA. bparker03@harthosp.org
Beth A
BA
Parker
Jeffrey A
JA
Capizzi
Amanda L
AL
Augeri
Adam S
AS
Grimaldi
C
C
Michael White
Paul D
PD
Thompson
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000069059:Atorvastatin; D001783:Blood Flow Velocity / Q000187:drug effects; D003237:Connecticut; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D015444:Exercise; D005260:Female; D005263:Femoral Artery / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006940:Hyperemia / Q000503:physiopathology; D008055:Lipids / Q000097:blood; D035002:Lower Extremity / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction; D010919:Placebos; D011758:Pyrroles / Q000008:administration & dosage*; D012039:Regional Blood Flow / Q000187:drug effects; D013997:Time Factors; D018608:Ultrasonography, Doppler; D014664:Vasodilation / Q000187:drug effects*
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D010919:Placebos; D011758:Pyrroles; D000069059:Atorvastatin